ViiV must take immediate action to grant a license for CAB-LA with open and transparent negotiations.
On 1st March, AfroCAB along with almost 200 community partners and individuals across the world, released a statement calling on ViiV Healthcare and GSK to immediately grant a broad generic license for cabotegravir long–acting injectable (CAB–LA), support effective technology transfer, and pursue widespread product
registration in all high–burden HIV countries. Following an initial statement that could be characterized as dismissive and evasive, ViiV later released an updated statement indicating an openness to pursuing a generic license for CAB–LA.
While the signatories appreciate the company’s responsiveness, ViiV remains opaque and uncollaborative, and key demands in the first letter went largely unanswered. This has left many concerns that without robust, transparent, and consultative actions by ViiV/GSK, access to CAB-LA will be delayed even further, prolonging the AIDS epidemic.
A newly released community statement raised those concerns again and re-emphasized the steps that must immediately be seen from ViiV/GSK providing a roadmap to access CAB-LA as quickly as possible.
Download the community response to ViiV’s recent statements on CAB-LA here.
Source : AfroCAB
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.